

Home

Home | Contact Us | Careers | Search

Acting on innovation

Newsroom

News Release

Bioniche Life Sciences Appoints New Member to its Board

13/06/02

BELLEVILLE, ON, June 13, 2002 – Bioniche Life Sciences Inc. (BNC: TSE) today announced the appointment of Mr. Jacques Lapointe to its Board of Directors.

"The appointment of Mr. Lapointe as an independent director to Bioniche's Board is befitting of our impressive three year growth and the strength of our late-stage pipeline," said Graeme McRae, President and CEO of Bioniche. "Mr. Lapointe's experience in this sector will prove extremely valuable as we continue our progress towards becoming a profitable industry leader."

"Both Bioniche's integrated business model and aggressive research pipeline intrigued me to accept this position. The combination of these two components of Bioniche reflects my own experience in both Big Pharma and biotech companies," said Jacques Lapointe.

Most recently, Mr. Lapointe served as President, Chief Operating Officer and Director of BioChem Pharma Inc. Prior to that, he worked for twelve years with Glaxo Wellcome plc with responsibilities as President and CEO of Glaxo Canada, Managing Director for the U.K., Regional Director for a number of other countries, and Worldwide Director of Business and Commercial Development. Prior to Glaxo Wellcome, Mr. Lapointe held roles of increasing responsibility through a 17 year tenure with Johnson & Johnson. This culminated in his position as Executive Vice-President for Sales and Marketing, Business Development and Technical Operations with McNeil Pharmaceuticals Canada Inc., a J&J subsidiary.

Mr. Lapointe is a Director of a number of public and private corporations and charities, including: Altarex

Categorio

Back

All Releases
Archived Relea
Animal Health

Corporate

Financial

Food Safety Human Health

Newsroom

News Releases Media Contact

Media Resources

Our Business

Management Team

Board of Directors Corporate Publications

Fact Sheets/ Backgrounders

Events

Q&A

· Latest News

June 29, 2006
Bioniche Presents
Additional Data on
Anticancer Activity of
Mycobacterial Cell WallDNA Complex (MCC)
Against Human Bladder
Cancer Cells

More +

June 27, 2006

Cameron Groome Joins Bioniche as Executive Vice-President, Corporate & Strategic Development

......

More :

Investors

4 Aug 2006 8:36:00

Check latest stock price



All prices delayed at least 15 minutes. Source: TSX Inc. Corp., Visible Genetics Inc.; ConjuChem Inc.; Procrea BioSciences Inc. (Chairman); and Galileo Genomics Inc. He also served as Chairman of the Pharmaceutical Manufacturers Association of Canada (PMAC), now known as Canada's Research-Based Pharmaceutical Companies (Rx&D).

Born in Ottawa, Canada, Mr. Lapointe received a Bachelor of Commerce degree as well as a MBA (Finance) from Concordia University in Montreal. He also completed an EPBA at Columbia University, New York.

About Bioniche Life Sciences Inc. Bioniche is a leading Canadian biopharmaceutical company that develops, manufactures and markets proprietary products for human and animal health markets worldwide. The Company is developing a pipeline of anti-cancer therapies based on its proprietary mycobacterial cell wall technologies. The Company employs more than 220 people in four business units: Bioniche Pharma, Bioniche Therapeutics, Bioniche Animal Health, and Bioniche Food Safety.

Bioniche Life Sciences Inc. trades on the Toronto Stock Exchange (TSX) under the symbol "BNC" and currently has 27,818,445 shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of Bioniche Life Sciences Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

Copyright 2004, Bioniche Life Sciences Inc. All rights reserved | Legal Disclaimer | Pr